Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight.

Cancer science - 1 May 2023

Fujiwara Yutaka, Makihara Reiko, Hase Tetsunari, Hashimoto Naozumi, Naito Tomoyuki, Tsubata Yukari, Okuno Takae, Takahashi Toshiaki, Kobayashi Haruki, Shinno Yuki, Zenke Yoshitaka, Ikeda Takaya, Hosomi Yukio, Watanabe Kageaki, Kitazono Satoru, Sakiyama Naomi, Makino Yoshinori, Yamamoto Noboru

Abstract excerpt

The safety of osimertinib is limited in patients with severe or moderate renal impairment, or low body weight. This study aimed to investigate the safety, pharmacokinetics (PK) and recommended dose (RD) of osimertinib in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with impaired renal function and low body weight. Thirty-one eligible patients were enrolled and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Body Weight

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Kidney

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Renal Insufficiency

Source

Open in PubMed Open full text

Identifiers

PMID: 36704833
DOI: 10.1111/cas.15736
PMCID: PMC10154887

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight.PMID 36704833Read ↗

Efficacy and safety of 40 mg osimertinib administered every other day for non-small cell lung cancer harboring an epidermal growth factor receptor mutation: A single-center retrospective cohort study.Semantic proximity Read ↗

Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment.Semantic proximity Read ↗

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.Semantic proximity Read ↗

Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Results from a Phase IV study in India.Semantic proximity Read ↗

Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting.Semantic proximity Read ↗

Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer.Semantic proximity Read ↗

Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).Semantic proximity Read ↗

Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70 years or older ('MONEY' trial).Semantic proximity Read ↗

Clinical Impact of Osimertinib Dose Reduction in the First-Line Setting on EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Monocentric StudySemantic proximity Read ↗

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.Semantic proximity Read ↗

Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study.Semantic proximity Read ↗

Reduced frequency dosing of osimertinib in EGFR-mutant non-small cell lung carcinoma: Real world dataSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.